Coagulation in Liver Disease: A Guide for the Clinician

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 9, 2013, Pages 1064-1074

  Northup, Patrick G ^a   Caldwell, Stephen H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Acute Liver Failure; Bleeding Portal Vein Thrombosis; Coagulation; Liver; Varices

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR; FIBRIN; FIBRINOGEN; GLYCOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN; PROCOAGULANT; SERUM ALBUMIN; THROMBIN; THROMBOPLASTIN; THROMBOPOIETIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE LIVER FAILURE; ANTICOAGULATION; ARTERIOGRAPHY; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; BRONCHOSCOPY; CATHETERIZATION; CENTRAL VENOUS CATHETER; CHRONIC LIVER DISEASE; COLONOSCOPY; CORONARY ARTERY; CRYOPRECIPITATE; DECOMPENSATED LIVER CIRRHOSIS; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; ELECTIVE SURGERY; ENDOTHELIAL DYSFUNCTION; ESOPHAGUS VARICES; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; FLOW MEASUREMENT; HEMOPHILIA A; HEMOSTASIS; HOSPITALIZATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL PRESSURE MONITORING; INVASIVE PROCEDURE; KIDNEY BIOPSY; KIDNEY FUNCTION; LABORATORY TEST; LIVER BIOPSY; LIVER TRANSPLANTATION; LUNG EMBOLISM; MOLECULAR WEIGHT; PARACENTESIS; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PATIENT CARE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; POLYPECTOMY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN THROMBOSIS; PORTOSYSTEMIC ANASTOMOSIS; POSITIVE FEEDBACK; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN C DEFICIENCY; PROTEIN DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; TOOTH EXTRACTION; TURNOVER TIME; UREMIA; VASCULAR ENDOTHELIUM; VASCULAR SURGERY; VENOUS THROMBOEMBOLISM;

ACUTE LIVER FAILURE; ALF; BLEEDING PORTAL VEIN THROMBOSIS; COAGULATION; ESOPHAGEAL VARICEAL BAND LIGATION; EVBL; FFP; FRESH FROZEN PLASMA; INR; INTERNATIONAL NORMALIZED RATIO; LIVER; LMWH; LOW-MOLECULAR-WEIGHT HEPARIN; PORTAL VEIN THROMBOSIS; PROTHROMBIN TIME; PT; PVT; VARICES; VENOUS THROMBOEMBOLISM; VITAMIN K ANTAGONIST; VKA; VON WILLEBRAND FACTOR; VTE; VWF;

BLOOD COAGULATION DISORDERS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; LIVER DISEASES;

EID: 84882837451     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.02.026     Document Type: Article

References (76)

1. Tripodi A., Primignani M., Mannucci P.M. Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med 2010, 5:7-12.
2. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N Engl J Med 2011, 365:147-156.
3. De Caterina M., Tarantino G., Farina C., et al. Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S. Haemostasis 1993, 23:229-235.
4. Tripodi A. Hemostasis in chronic liver disease. J Thromb Haemost 2006, 4:2064-2065.
5. Kajihara M., Kato S., Okazaki Y., et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003, 37:1267-1276.
6. Kajihara M., Okazaki Y., Kato S., et al. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007, 22:112-118.
7. Pradella P., Bonetto S., Turchetto S., et al. Platelet production and destruction in liver cirrhosis. J Hepatol 2011, 54:894-900.
8. Martin T.G., Somberg K.A., Meng Y.G., et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997, 127:285-288.
9. La Mura V., Reverter J.C., Flores-Arroyo A., et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011, 60:1133-1138.
10. Lisman T., Bongers T.N., Adelmeijer J., et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006, 44:53-61.
11. Lisman T., Adelmeijer J., de Groot P.G., et al. No evidence for an intrinsic platelet defect in patients with liver cirrhosis: studies under flow conditions. J Thromb Haemost 2006, 4:2070-2072.
12. Tripodi A., Primignani M., Chantarangkul V., et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006, 44:440-445.
13. Sleisenger M.H., Feldman M., Friedman L.S., et al. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management 2010, Saunders/Elsevier, Philadelphia.
14. Tripodi A., Salerno F., Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005, 41:553-558.
15. Tripodi A., Primignani M., Chantarangkul V., et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009, 137:2105-2111.
16. Ferro D., Basili S., Lattuada A., et al. Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: a potential role for endothelial procoagulant activation. Ital J Gastroenterol Hepatol 1997, 29:434-440.
17. Goulis J., Armonis A., Patch D., et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998, 27:1207-1212.
18. Sagripanti A., Cupisti A., Baicchi U., et al. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993, 63:273-278.
19. Trotter J.F., Brimhall B., Arjal R., et al. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004, 10:995-1000.
20. Lisman T., van Leeuwen Y., Adelmeijer J., et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int 2008, 28:1344-1351.
21. Tripodi A., Chantarangkul V., Primignani M., et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007, 46:520-527.
22. Gilmore I.T., Burroughs A., Murray-Lyon I.M., et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995, 36:437-441.
23. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981, 26:388-393.
24. Denzer U., Helmreich-Becker I., Galle P.R., et al. Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol 2003, 98:893-900.
25. Segal J.B., Dzik W.H. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005, 45:1413-1425. Transfusion Medicine/Hemostasis Clinical Trials Network.
26. Bruzzi J.F., O'Connell M.J., Thakore H., et al. Transjugular liver biopsy: assessment of safety and efficacy of the Quick-Core biopsy needle. Abdom Imaging 2002, 27:711-715.
27. Grabau C.M., Crago S.F., Hoff L.K., et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004, 40:484-488.
28. Jeon J.W., Shin H.P., Lee J.I., et al. The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis. Surg Endosc 2012, 26:3258-3263.
29. Baltz J.G., Argo C.K., Al-Osaimi A.M., et al. Mortality after percutaneous endoscopic gastrostomy in patients with cirrhosis: a case series. Gastrointest Endosc 2010, 72:1072-1075.
30. Stanca C.M., Montazem A.H., Lawal A., et al. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg 2010, 68:138-143.
31. Townsend J.C., Heard R., Powers E.R., et al. Usefulness of international normalized ratio to predict bleeding complications in patients with end-stage liver disease who undergo cardiac catheterization. Am J Cardiol 2012, 110:1062-1065.
32. Youssef W.I., Salazar F., Dasarathy S., et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003, 98:1391-1394.
33. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 2009, 49:1017-1044.
34. Patel I.J., Davidson J.C., Nikolic B., et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2012, 23:727-736.
35. Seeff L.B., Everson G.T., Morgan T.R., et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010, 8:877-883.
36. Caldwell S., Northup P.G. Bleeding complication with liver biopsy: is it predictable?. Clin Gastroenterol Hepatol 2010, 8:826-829.
37. Chang Y.W., Liao C.H., Day Y.J. Platelet function analyzer (PFA-100) offers higher sensitivity and specificity than thromboelastography (TEG) in detection of platelet dysfunction. Acta Anaesthesiol Taiwan 2009, 47:110-117.
38. Ferro D., Quintarelli C., Lattuada A., et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996, 23:1377-1383.
39. Basili S., Ferro D., Leo R., et al. Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis: the CALC group-Coagulation Abnormalities in Liver Cirrhosis. J Hepatol 1996, 24:574-580.
40. Arif S., Khan A.S., Khan A.R. Changes in fibrinogen level in liver cirrhosis. J Ayub Med Coll Abbottabad 2002, 14:19-21.
41. Kang Y.G., Martin D.J., Marquez J., et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985, 64:888-896.
42. Ranucci M., Solomon C. Supplementation of fibrinogen in acquired bleeding disorders: experience, evidence, guidelines, and licences. Br J Anaesth 2012, 109:135-137.
43. Gunawan B., Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006, 23:115-120.
44. Wang J.S., Lin C.Y., Hung W.T., et al. Thromboelastogram fails to predict postoperative hemorrhage in cardiac patients. Ann Thorac Surg 1992, 53:435-439.
45. De Matteis F., Barbano G. The thromboelastogram in acute myocardial infarction not treated with anticoagulants. Panminerva Med 1961, 3:124-126.
46. Salooja N., Perry D.J. Thrombelastography. Blood Coagul Fibrinolysis 2001, 12:327-337.
47. Tripodi A., Primignani M., Chantarangkul V., et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009, 124:132-136.
48. Viola F., Kramer M.D., Lawrence M.B., et al. Sonorheometry: a noncontact method for the dynamic assessment of thrombosis. Ann Biomed Eng 2004, 32:696-705.
49. Tripodi A., Primignani M., Lemma L., et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010, 52:249-255.
50. Rautou P.E., Bresson J., Sainte-Marie Y., et al. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology 2012, 143:166-176.
51. Groszmann R.J., Garcia-Tsao G., Bosch J., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005, 353:2254-2261.
52. Garcia-Tsao G., Groszmann R.J., Fisher R.L., et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985, 5:419-424.
53. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988, 319:983-989. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices.
54. Violi F., Leo R., Basili S., et al. Association between prolonged bleeding time and gastrointestinal hemorrhage in 102 patients with liver cirrhosis: results of a retrospective study. Haematologica 1994, 79:61-65.
55. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46:922-938.
56. Qureshi W., Adler D.G., Davila R., et al. ASGE guideline: the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastrointest Endosc 2005, 62:651-655.
57. Vieira da Rocha E.C., D'Amico E.A., Caldwell S.H., et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol 2009, 7:988-993.
58. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010, 53:762-768. Baveno V faculty.
59. Kravetz D., Sikuler E., Groszmann R.J. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986, 90:1232-1240.
60. Castañeda B., Morales J., Lionetti R., et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 2001, 33:821-825.
61. Villanueva C., Colomo A., Bosch A., et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013, 368:11-21.
62. Holland L.L., Brooks J.P. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006, 126:133-139.
63. Northup P.G., Wanamaker R.C., Lee V.D., et al. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg 2005, 242:244-251.
64. Chitlur M., Sorensen B., Rivard G.E., et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia 2011, 17:532-537.
65. Amitrano L., Guardascione M.A., Brancaccio V., et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004, 40:736-741.
66. Wanless I.R., Wong F., Blendis L.M., et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995, 21:1238-1247.
67. Senzolo M., Sartori T.M., Rossetto V., et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012, 32:919-927.
68. Villa E., Cammà C., Marietta M., et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012, 143:1253-1260.
69. García-Fuster M.J., Abdilla N., Fabiá M.J., et al. [Venous thromboembolism and liver cirrhosis]. Rev Esp Enferm Dig 2008, 100:259-262.
70. Northup P.G., McMahon M.M., Ruhl A.P., et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006, 101:1524-1528. quiz 1680.
71. Søgaard K.K., Horváth-Puhó E., Grønbaek H., et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009, 104:96-101.
72. Intagliata N., Henry Z., Shah N.L., et al. Prophylactic anticoagulation for deep venous thrombosis in hospitalized cirrhosis patients is safe and does not lead to increased bleeding events. Hepatology 2011, 54:1253A.
73. Lee W.M. Acute liver failure in the United States. Semin Liver Dis 2003, 23:217-226.
74. Stravitz R.T., Lisman T., Luketic V.A., et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012, 56:129-136.
75. Lisman T., Bakhtiari K., Adelmeijer J., et al. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012, 10:1312-1319.
76. Shami V.M., Caldwell S.H., Hespenheide E.E., et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003, 9:138-143.